GlassScriptPhysician profile
Foram Patel
NPI 1386364636
$6,949.37
in general payments reported to CMS, 2019-2025
30 companies · $2,807 in 2025
The $2,807 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $182 · 2023: $1,487 · 2024: $2,473 · 2025: $2,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,767.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $819.95 | 2022-2024 | |
| Abbvie INC. | $797.27 | 2024-2025 | |
| Axsome Therapeutics, INC. | $618.10 | 2024-2025 | Auvelity, Sunosi |
| Viiv Healthcare Company | $547.39 | 2023-2024 | Dovato, Apretude, Rukobia |
| Vanda Pharmaceuticals INC. | $539.02 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $496.42 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $479.67 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $434.95 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $286.45 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Biotech, INC. | $238.12 | 2022-2023 | Symtuza |
| Alkermes, INC. | $205.70 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $204.33 | 2024-2025 | Spravato, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $197.90 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $167.53 | 2024-2025 | Rexulti |
| Napo Pharmaceuticals INC | $144.57 | 2022-2023 | Mytesi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $137.82 | 2024-2025 | Wellbutrin, Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $123.02 | 2024-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $68.13 | 2023-2024 | Pifeltro, Delstrigo, Dificid |
| Indivior INC. | $57.59 | 2025 | Sublocade |
| Bayer Healthcare Pharmaceuticals INC. | $53.57 | 2024 | |
| Collegium Pharmaceutical, INC. | $52.47 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $50.11 | 2024-2025 | |
| Ironshore Pharmaceuticals INC. | $42.02 | 2024 | |
| Idorsia Pharmaceuticals US INC | $41.39 | 2024 | Quviviq |
| Livanova USA, INC. | $39.63 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Lilly USA, LLC | $27.77 | 2025 | Zepbound |
| Dynavax Technologies Corporation | $23.27 | 2023 | Heplisav-B |
| Tris Pharma INC | $19.07 | 2024 | Dyanavel Xr |
| Luye Pharma (USA) LTD. | $18.23 | 2025 | Erzofri Extended-Release |
| Theratechnologies INC. | $17.91 | 2023 | Trogarzo, Egrifta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Foram Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.